USP Class VI is no longer the gold standard. Are you ready for what’s next?
The United States Pharmacopeia (USP) has moved away from traditional Class VI testing. Once regarded as the benchmark for material safety, USP Class VI is now acknowledged as offering limited insight and must be incorporated into a comprehensive, risk-based evaluation strategy aligned with ISO 10993.
What you’ll learn:
Whether you're in regulatory affairs, R&D, or quality assurance, this session will help you stay ahead of the curve and prepare for the future of biocompatibility assessment.
For any information you can contact us at: medical-device@bpt.eurofinseu.com
Registration: Click here to register.